# Dysport in the Treatment of Glabellar Lines in Chinese Subjects

> **NCT02450526** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 520 (actual)

## Conditions studied

- Glabellar Lines

## Interventions

- **BIOLOGICAL:** Botulinum toxin type A
- **BIOLOGICAL:** Botulinum toxin type A
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02450526
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-07
- **Final completion:** 2017-09-06
- **Target enrollment:** 520 (ACTUAL)
- **Last updated:** 2019-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02450526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02450526, "Dysport in the Treatment of Glabellar Lines in Chinese Subjects". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02450526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*